Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
samRNA SARS-CoV-2 Vaccine Study (GRT-R912/914/918) in Healthy Adults and PLWH
NCT05435027Phase 1Completed
- Sponsor
- Gritstone bio, Inc.
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GRT-R912 and GRT-R918 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Gritstone bio, Inc. Primary endpoints: Solicited Local Reactogenicity Signs and Symptoms up to 7 days, Solicited Systemic Reactogenicity Signs and Symptoms up to 7 days and 2 more. Started Feb 2022; status: completed.
02
Drugs
GRT-R912GRT-R918
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05435027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435027.